SK BIOPHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86,600 KRW | -1.93% |
|
+3.96% | -13.75% |
| 01-30 | SK Biopharmaceuticals Swings to Profit in Q4 | MT |
| 2023 | SK Group Advances Net Zero Transition via Key Renewable Energy Deal | MT |
ETFs positioned on SK Biopharmaceuticals Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.83% | 2 M€ | -14.14% | ||
| 0.08% | 15 M€ | +12.19% | ||
| 0.03% | 2,808 M€ | +8.23% | - | |
| 0.03% | 441 M€ | +6.14% | - | |
| 0.03% | 149 M€ | +3.96% | - | |
| 0.03% | 4 M€ | -4.41% | - | |
| 0.01% | 7 M€ | +2.57% | - | |
| 0.01% | 117 M€ | +2.20% | - | |
| 0.00% | 34 M€ | +6.21% | - | |
| 0.00% | 34 M€ | +2.67% | - | |
| 0.00% | 302 M€ | +4.66% | - | |
| 0.00% | 39 M€ | +3.82% | - |
SK Biopharmaceuticals Co Ltd is a Korea-based company mainly engages in the development and manufacture of pharmaceuticals. The Company mainly develops and produces pharmaceuticals including epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs, among others. The Company also engages in the new drug development business.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
86,600
KRW
Average target price
106,133
KRW
Spread / Average Target
+22.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.75% | 5.05B | |
| +5.48% | 69.91B | |
| +12.55% | 9.24B | |
| +42.38% | 4.47B | |
| +4.51% | 3.92B | |
| -19.05% | 2.41B | |
| -28.72% | 2.23B | |
| +11.13% | 2.02B | |
| +6.08% | 1.66B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- A326030 Stock
- Funds and ETFs SK Biopharmaceuticals Co., Ltd.
